Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVA...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Vaccine Immunol
Главные авторы: Frey, Sharon E., Peiperl, Laurence, McElrath, M. Juliana, Kalams, Spyros, Goepfert, Paul A., Keefer, Michael C., Baden, Lindsey R., Lally, Michelle A., Mayer, Kenneth, Blattner, William A., Harro, Clayton D., Hammer, Scott M., Gorse, Geoffrey J., Hural, John, Tomaras, Georgia D., Levy, Yves, Gilbert, Peter, deCamp, Allan, Russell, Nina D., Elizaga, Marnie, Allen, Mary, Corey, Lawrence
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2014
Предметы:
Vaccines
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4248765/
https://ncbi.nlm.nih.gov/pubmed/25253665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00450-14
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы